ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM
Abstract Number: 2387
Resurrecting Triamcinolone Hexacetonide (the Steroid Formerly Known as Aristospan®): Efficacy and Safety of a Compounded Preparation of Triamcinolone Hexacetonide for Intra-Articular Injection in Children with Arthritis
Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis
9:00AM-11:00AM
Abstract Number: 2543
Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds
9:00AM-11:00AM
Abstract Number: 2139
Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2526
Revealing and Addressing Knowledge Gaps Regarding Biosimilars in Rheumatology Practice with Targeted Continuing Education and Patient Surveys
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds
9:00AM-11:00AM
Abstract Number: 2256
Rheumatic Diseases Associated with Neuromyelitis Optica Spectrum Disorders (NMOSD): Prevalence, Clinical, Laboratory and Imaging Characteristics
Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease
9:00AM-11:00AM
Abstract Number: 2332
Rheumatoid Arthritis Effect´s on Bone Mass and Muscle
Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster
9:00AM-11:00AM
Abstract Number: 2551
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds
9:00AM-11:00AM
Abstract Number: 1979
Rheumatoid Arthritis-Associated Genetic Alteration Defines a New Promoter for Peptydil Arginine Deiminase 4 Gene
Genetics, Genomics and Proteomics Poster
9:00AM-11:00AM
Abstract Number: 2051
Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis
Rheumatoid Arthritis – Etiology and Pathogenesis Poster III
9:00AM-11:00AM
Abstract Number: 2438
Risk and Severity of Adverse Pregnancy Outcomes in Women with Systemic Sclerosis in Taiwan
Reproductive Issues in Rheumatic Disorders Poster
9:00AM-11:00AM
Abstract Number: 2358
Risk Factors for Persistent Discordance in Global Assessment of Rheumatoid Arthritis (RA) Disease Activity between RA Patients and Their Physicians: Analysis Based on a Nationwide RA Database (2011 to 2016)
Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives
9:00AM-11:00AM
Abstract Number: 2276
Risk of Hemorrhagic Strokes in Patients with Adenosine Deaminase 2 Deficiency
Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease
9:00AM-11:00AM
Abstract Number: 2456
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures
9:00AM-11:00AM
Abstract Number: 2455
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures
9:00AM-11:00AM
Abstract Number: 2742
Rituximab Versus Cyclophosphamide for Vasculitic Neuropathy: A Patient Reported Outcomes Study
Vasculitis – ANCA-Associated Poster II
  • «Previous Page
  • 1
  • …
  • 41
  • 42
  • 43
  • 44
  • 45
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology